Aperio Group LLC Trims Position in Core Laboratories (NYSE:CLB)


Share on StockTwits

Aperio Group LLC decreased its position in shares of Core Laboratories (NYSE:CLB) by 0.5% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 316,366 shares of the oil and gas company’s stock after selling 1,549 shares during the period. Aperio Group LLC’s holdings in Core Laboratories were worth $8,387,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Marshall Wace LLP acquired a new position in Core Laboratories during the first quarter worth approximately $30,000. Aigen Investment Management LP acquired a new position in Core Laboratories during the third quarter worth approximately $36,000. First Bank & Trust increased its position in Core Laboratories by 155.9% during the third quarter. First Bank & Trust now owns 3,007 shares of the oil and gas company’s stock worth $46,000 after purchasing an additional 1,832 shares during the last quarter. Gagnon Securities LLC acquired a new position in Core Laboratories during the third quarter worth approximately $155,000. Finally, Mraz Amerine & Associates Inc. acquired a new position in Core Laboratories during the third quarter worth approximately $160,000. 92.69% of the stock is currently owned by institutional investors and hedge funds.

CLB opened at $35.36 on Tuesday. The company has a fifty day simple moving average of $34.09 and a 200 day simple moving average of $23.91. The firm has a market cap of $1.58 billion, a price-to-earnings ratio of -15.58, a PEG ratio of 12.83 and a beta of 3.38. Core Laboratories has a twelve month low of $6.68 and a twelve month high of $37.08. The company has a current ratio of 0.99, a quick ratio of 0.74 and a debt-to-equity ratio of 2.64.

Core Laboratories (NYSE:CLB) last posted its quarterly earnings data on Tuesday, January 26th. The oil and gas company reported $0.18 EPS for the quarter, beating the Zacks’ consensus estimate of $0.16 by $0.02. Core Laboratories had a negative net margin of 19.02% and a positive return on equity of 45.39%. The firm had revenue of $113.80 million for the quarter, compared to the consensus estimate of $108.40 million. During the same period in the prior year, the firm posted $0.38 EPS. The firm’s revenue was down 27.4% compared to the same quarter last year. On average, analysts forecast that Core Laboratories will post 0.78 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, February 16th. Shareholders of record on Monday, January 25th were paid a dividend of $0.01 per share. The ex-dividend date of this dividend was Friday, January 22nd. This represents a $0.04 dividend on an annualized basis and a yield of 0.11%. Core Laboratories’s dividend payout ratio (DPR) is 2.23%.

Several equities analysts recently commented on the stock. Wolfe Research raised shares of Core Laboratories from an “underperform” rating to a “market perform” rating in a research report on Monday, January 11th. Cowen dropped their price target on shares of Core Laboratories from $26.00 to $20.00 and set a “market perform” rating for the company in a research report on Wednesday, November 11th. Morgan Stanley raised shares of Core Laboratories from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, November 10th. Smith Barney Citigroup increased their price objective on shares of Core Laboratories from $16.00 to $30.00 in a research report on Tuesday, December 15th. Finally, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell increased their price objective on shares of Core Laboratories from $16.00 to $30.00 in a research report on Tuesday, December 15th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have issued a buy rating to the company’s stock. Core Laboratories currently has an average rating of “Hold” and an average price target of $21.22.

Core Laboratories Profile

Core Laboratories N.V. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. The company operates in two segments, Reservoir Description and Production Enhancement. The Reservoir Description segment includes the characterization of petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs.

See Also: Bull Market

Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories (NYSE:CLB).

Institutional Ownership by Quarter for Core Laboratories (NYSE:CLB)

Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.